These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 11522647

  • 1. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
    Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, Baselga J.
    Cancer Res; 2001 Sep 01; 61(17):6500-10. PubMed ID: 11522647
    [Abstract] [Full Text] [Related]

  • 2. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM, Saigal B, Donato NJ.
    J Cell Physiol; 2005 Nov 01; 205(2):218-27. PubMed ID: 15887238
    [Abstract] [Full Text] [Related]

  • 3. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.
    Cohen EE, Lingen MW, Zhu B, Zhu H, Straza MW, Pierce C, Martin LE, Rosner MR.
    Cancer Res; 2006 Jun 15; 66(12):6296-303. PubMed ID: 16778206
    [Abstract] [Full Text] [Related]

  • 4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 5. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.
    Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, Grandis JR.
    Cancer Res; 2004 Sep 01; 64(17):6166-73. PubMed ID: 15342401
    [Abstract] [Full Text] [Related]

  • 6. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
    Thottassery JV, Sun Y, Westbrook L, Rentz SS, Manuvakhova M, Qu Z, Samuel S, Upshaw R, Cunningham A, Kern FG.
    Cancer Res; 2004 Jul 01; 64(13):4637-47. PubMed ID: 15231676
    [Abstract] [Full Text] [Related]

  • 7. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G.
    Clin Cancer Res; 2003 Jun 01; 9(6):2316-26. PubMed ID: 12796401
    [Abstract] [Full Text] [Related]

  • 8. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B, Chang CM, Yuan M, McKenna WG, Shu HK.
    Cancer Res; 2003 Nov 01; 63(21):7443-50. PubMed ID: 14612544
    [Abstract] [Full Text] [Related]

  • 9. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY, Lee SW, Hong JP, Chang SE, Choe H, Choi J.
    Cancer Lett; 2009 Oct 08; 283(2):135-42. PubMed ID: 19380191
    [Abstract] [Full Text] [Related]

  • 10. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 11. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor.
    Lui VW, Thomas SM, Zhang Q, Wentzel AL, Siegfried JM, Li JY, Grandis JR.
    Oncogene; 2003 Sep 18; 22(40):6183-93. PubMed ID: 13679857
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE.
    J Clin Oncol; 2003 May 15; 21(10):1980-7. PubMed ID: 12743152
    [Abstract] [Full Text] [Related]

  • 13. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
    Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL.
    Oncogene; 2002 Sep 12; 21(41):6255-63. PubMed ID: 12214266
    [Abstract] [Full Text] [Related]

  • 14. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
    O-charoenrat P, Modjtahedi H, Rhys-Evans P, Court WJ, Box GM, Eccles SA.
    Cancer Res; 2000 Feb 15; 60(4):1121-8. PubMed ID: 10706134
    [Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.
    Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD, Grandis JR.
    Cancer Res; 2003 Sep 01; 63(17):5629-35. PubMed ID: 14500405
    [Abstract] [Full Text] [Related]

  • 17. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
    Chan KC, Knox WF, Gee JM, Morris J, Nicholson RI, Potten CS, Bundred NJ.
    Cancer Res; 2002 Jan 01; 62(1):122-8. PubMed ID: 11782368
    [Abstract] [Full Text] [Related]

  • 18. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A.
    J Cell Physiol; 2003 Apr 01; 195(1):139-50. PubMed ID: 12599217
    [Abstract] [Full Text] [Related]

  • 19. Epidermal growth factor-induced cyclooxygenase-2 expression in oral squamous cell carcinoma cell lines is mediated through extracellular signal-regulated kinase 1/2 and p38 but is Src and nuclear factor-kappa B independent.
    Husvik C, Bryne M, Halstensen TS.
    Eur J Oral Sci; 2009 Oct 01; 117(5):528-35. PubMed ID: 19758248
    [Abstract] [Full Text] [Related]

  • 20. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A.
    Clin Cancer Res; 2006 Jan 15; 12(2):617-25. PubMed ID: 16428508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.